Skip to main content

Advertisement

Log in

Sentinel Lymph Node Dissection in Primary Melanoma Reduces Subsequent Regional Lymph Node Metastasis as Well as Distant Metastasis After Nodal Involvement

  • Melanomas
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

In many countries sentinel lymph node dissection (SLND) followed by complete lymphadenectomy if positive is routinely performed treatment for primary cutaneous melanoma. However, the potential survival benefit of SLND is still controversial.

Methods

Patients with primary cutaneous melanoma (tumor thickness 1.00 mm or greater) diagnosed in the Department of Dermatology, University of Tuebingen, Germany between 1991 and 2000 were included in the study. A total of 439 patients who received SLND were compared retrospectively with 440 patients without SLND with regards to occurring patterns of metastases and disease-free and overall survival. SLND-positive cases and SLND-negative patients with subsequent development of regional lymph node metastasis (SLND-LN+) were compared with non-SLND patients who had developed regional lymph node metastasis (non-SLND-LN+).

Results

Regional lymph node metastases as the first recurrence occurred more frequently in the non-SLND collective (16.5%) compared with the SLND group (7.3%; P = 0.001), whereas satellite/in-transit metastases and distant metastases did not differ. Driven by the reduction of regional lymph node metastases, disease-free survival was improved in the SLND collective (P = 0.003). No significant difference in overall survival was observed (P = 0.090).The risk of dying from melanoma was 2.2 times higher in the non-SLND-LN+ group than in the SLND-LN+ group (P = 0.009), while the risk of developing distant metastasis was 2.3 times higher (P = 0.002).

Conclusions

SLND reduced subsequent regional lymph node metastases and improved disease-free survival, while overall survival remained unaffected. SLND reduced distant metastases and improved overall survival in the subgroups of patients with regional lymph node involvement.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54(3):131–49.

    Article  PubMed  Google Scholar 

  2. Cascinelli N, Belli F, Santinami M, Fait V, Testori A, Ruka W, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol. 2000;7(6):469–74.

    Article  CAS  PubMed  Google Scholar 

  3. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg Oncol. 1991;214(4):491–9.

    CAS  Google Scholar 

  4. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17(3):976–83.

    CAS  PubMed  Google Scholar 

  5. Kettlewell S, Moyes C, Bray C, Soutar D, MacKay A, Byrne D, et al. Value of sentinel node status as a prognostic factor in melanoma: prospective observational study. BMJ. 2006;332(7555):1423.

    Article  PubMed  Google Scholar 

  6. Yee VS, Thompson JF, McKinnon JG, Scolyer RA, Li LX, McCarthy WH, et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol. 2005;12(6):429–39.

    Article  PubMed  Google Scholar 

  7. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635–48.

    CAS  PubMed  Google Scholar 

  8. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307–17.

    Article  CAS  PubMed  Google Scholar 

  9. Morton DL, Hoon DS, Cochran AJ, Turner RR, Essner R, Takeuchi H, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg Oncol. 2003;238(4):538–49.

    Google Scholar 

  10. Medalie N, Ackerman AB. Sentinel node biopsy has no benefit for patients whose primary cutaneous melanoma has metastasized to a lymph node and therefore should be abandoned now. Br J Dermatol. 2004;151(2):298–307.

    Article  CAS  PubMed  Google Scholar 

  11. Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol. 2002;147(1):62–70.

    Article  CAS  PubMed  Google Scholar 

  12. Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg Oncol. 2005;242(3):302–11.

    Google Scholar 

  13. Morton DL, Cochran AJ, Thompson JF. The rationale for sentinel-node biopsy in primary melanoma. Nat Clin Pract Oncol. 2008;5(9):510–1.

    Article  PubMed  Google Scholar 

  14. Cochran AJ, Morton DL. Detection of clinically relevant melanoma metastases requires focused, not exhaustive, evaluation of sentinel lymph nodes. Am J Surg Pathol. 2006;30(3):419–20.

    PubMed  Google Scholar 

  15. Cochran AJ, Huang RR, Lee J, Itakura E, Leong SP, Essner R. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 2006;6(9):659–70.

    Article  CAS  PubMed  Google Scholar 

  16. Balch CM, Cascinelli N. Sentinel-node biopsy in melanoma. N Engl J Med. 2006;355(13):1370–1.

    Article  CAS  PubMed  Google Scholar 

  17. Ross MI, Gershenwald JE. How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)? Ann Surg Oncol. 2008;15(3):670–3.

    Article  PubMed  Google Scholar 

  18. Thomas JM. Prognostic false-positivity of the sentinel node in melanoma. Nat Clin Pract Oncol. 2008;5(1):18–23.

    Article  PubMed  Google Scholar 

  19. Wagner JD, Gordon MS, Chuang TY, Coleman JJ, III. Current therapy of cutaneous melanoma. Plast Reconstr Surg. 2000;105(5):1774–99.

    Article  CAS  PubMed  Google Scholar 

  20. Blaheta HJ, Ellwanger U, Schittek B, Sotlar K, MacZey E, Breuninger H, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol. 2000;114(4):637–42.

    Article  CAS  PubMed  Google Scholar 

  21. Garbe C, Paul A, Kohler-Spath H, Ellwanger U, Stroebel W, Schwarz M, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21(3):520–9.

    Article  PubMed  Google Scholar 

  22. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622–34.

    CAS  PubMed  Google Scholar 

  23. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial WHO Melanoma Programme. Lancet. 1998;351(9105):793–6.

    Article  CAS  PubMed  Google Scholar 

  24. Kretschmer L, Hilgers R, Mohrle M, Balda BR, Breuninger H, Konz B, et al. Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer. 2004;40(2):212–8.

    Article  CAS  PubMed  Google Scholar 

  25. Arens A, Osinga J, Schwipper V, Schober O, Tilkorn H, Liebau J. [Sentinel lymph node dissection in patients with malignant melanoma Diagnostic and therapeutic standards]. Chirurg. 2003;74(7):665–70.

    Article  CAS  PubMed  Google Scholar 

  26. Blum A, Schlagenhauff B, Stroebel W, Breuninger H, Rassner G, Garbe C. Ultrasound examination of regional lymph nodes significantly improves early detection of locoregional metastases during the follow-up of patients with cutaneous melanoma: results of a prospective study of 1288 patients. Cancer. 2000;88(11):2534–9.

    Article  CAS  PubMed  Google Scholar 

  27. Berk DR, Johnson DL, Uzieblo A, Kiernan M, Swetter SM. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004. Arch Dermatol. 2005;141(8):1016–22.

    Article  PubMed  Google Scholar 

  28. Cascinelli N, Bombardieri E, Bufalino R, Camerini T, Carbone A, Clemente C, et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol. 2006;24(27):4464–71.

    Article  PubMed  Google Scholar 

  29. Cuchet E, Pinel N, Corcella D, Vuillez JP, Lebeau J, Moutet F, et al. Sentinel lymph node biopsy in cutaneous melanoma: outcome after 5-years follow-up. Eur J Dermatol. 2007;17(5):387–91.

    PubMed  Google Scholar 

  30. Debarbieux S, Duru G, Dalle S, Beatrix O, Balme B, Thomas L. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection. Br J Dermatol. 2007;157(1):58–67.

    Article  CAS  PubMed  Google Scholar 

  31. Roaten JB, Pearlman N, Gonzalez R, Gonzalez R, McCarter MD. Identifying risk factors for complications following sentinel lymph node biopsy for melanoma. Arch Surg. 2005;140(1):85–9.

    Article  PubMed  Google Scholar 

  32. Wasserberg N, Tulchinsky H, Schachter J, Feinmesser M, Gutman H. Sentinel-lymph-node biopsy (SLNB) for melanoma is not complication-free. Eur J Surg Oncol. 2004;30(8):851–6.

    Article  CAS  PubMed  Google Scholar 

  33. Thomas JM, Clark MA. Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. Eur J Surg Oncol. 2004;30(6):686–91.

    Article  CAS  PubMed  Google Scholar 

  34. Kang JC, Wanek LA, Essner R, Faries MB, Foshag LJ, Morton DL. Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol. 2005;23(21):4764–70.

    Article  PubMed  Google Scholar 

  35. Kretschmer L, Beckmann I, Thoms KM, Haenssle H, Bertsch HP, Neumann C. Sentinel lymphonodectomy does not increase the risk of loco-regional cutaneous metastases of malignant melanomas. Eur J Cancer. 2005;41(4):531–8.

    Article  CAS  PubMed  Google Scholar 

  36. Pawlik TM, Ross MI, Thompson JF, Eggermont AM, Gershenwald JE. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol. 2005;23(21):4588–90.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Claus Garbe MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leiter, U., Buettner, P.G., Bohnenberger, K. et al. Sentinel Lymph Node Dissection in Primary Melanoma Reduces Subsequent Regional Lymph Node Metastasis as Well as Distant Metastasis After Nodal Involvement. Ann Surg Oncol 17, 129–137 (2010). https://doi.org/10.1245/s10434-009-0780-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-009-0780-2

Keywords

Navigation